Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25319549 | 0.99 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL25319554 | 0.97 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL30551502 | 0.97 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL25319926 | 0.87 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL25324134 | 0.83 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL14738462 | 0.82 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL30099393 | 0.80 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL31360546 | 0.79 | F2RL1 (0.34) | DGAT1 | |
| SCHEMBL25049259 | 0.79 | MAPT (0.32) | DGAT1 | |
| SCHEMBL26353142 | 0.78 | DGAT1 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-11-16 | — | — | US | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | DGAT1 4478/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | DGAT1 4748/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | DGAT1 4151/4885 |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | DGAT1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.